Skip to main content
. Author manuscript; available in PMC: 2014 Jun 10.
Published in final edited form as: J Acquir Immune Defic Syndr. 2006 Jan 1;41(1):31–36. doi: 10.1097/01.qai.0000191281.77954.27

TABLE 2.

Treatment Regimen, Duration and Outcome for Subjects Receiving HCV Therapy

Patient Weight HCV Genotype HCV RNA (IU/mL) First Abnormal ALT to Start
of HCV Therapy		 HCV Diagnosis to Start
of HCV Therapy
3 88 kg 1a 2.0 million 2 wks 2 wks
4 71 kg 1b 140,000 11 wks 4 wks
5 87 kg 2 762 7 wks 7 wks
6 80 kg 1 6.0 million 12 wks 12 wks
Patient HCV Treatment Length of Therapy Complications of
HCV Therapy		 Dose Reduction Use of
Growth Factors		 Outcome
3 PEG IFN α-2a 180 mcg/wk +RBV 1000 mg/day 48 wks Anemia, Neutropenia, Depression IFN decreased to 135 mcg/wk — EVR, SVR
4 PEG IFN α-2a 180 mcg/wk +RBV 1000 mg/day 48 wks Anemia, Neutropenia, Depression IFN decreased to 135 mcg/wk Epo, G-CSF EVR, ETR*
5 PEG IFN α-2a 180 mcg/wk +RBV 1000 mg/day 24 wks Anemia, Neutropenia, Depression IFN decreased to 135 mcg/wk Epo, G-CSF EVR, SVR
6 PEG IFN α-2a 180 mcg/wk +RBV 1000 mg/day 48 wks Anemia, Depression — Epo EVR, No ETR
*

SVR data not yet available.

Epo indicates erythropoetin; EVR, early virologic response; ETR, end treatment response; PEG IFN, pegylated interferon; RBV, ribavirin; and SVR, sustained virologic response.